by Jordana Choucair | Jan 19, 2023 | Life Sciences
The National Institute of Allergy and Infectious Diseases reported that a Phase 3 clinical trial of Janssen’s HIV vaccine was stopped because the vaccine was ineffective. The trial began in 2019 and included 3,900 gay men and transgender people at over 50 sites in...
by Jordana Choucair | Jan 19, 2023 | Opioid/Substance Use Disorders
West Virginia State Attorney General Patrick Morrisey announced the state has agreed to an $83 million settlement with Walgreens Boots Alliance Inc. to resolve a lawsuit alleging that the company’s failed control measures contributed to an oversupply of opioids...
by Jordana Choucair | Jan 19, 2023 | Providers
KFF published a synthesis of recent studies on the economic impact of Medicaid expansion on providers. Thirty-nine states plus Washington D.C. have adopted Medicaid expansion under the Affordable Care Act (ACA), with the federal government covering 90 percent of the...
by Jordana Choucair | Jan 18, 2023 | Access & Coverage
Providers warn that the anticipated end of the COVID-19 public health emergency (PHE) will cause a “disruptive” and “abrupt return” to the old way of dispensing controlled substances. The PHE allowed physicians to prescribe controlled substances remotely. After the...
by Jordana Choucair | Jan 18, 2023 | Life Sciences
Moderna Inc. said its experimental RSV vaccine was 83.7 percent effective in a large clinical trial at lowering the risk of a viral respiratory disease in older adults. The company said it will apply for U.S. approval in the coming months, potentially allowing the...
by Jordana Choucair | Jan 18, 2023 | Payers
A new Centers for Disease and Control Prevention (CDC) report shows that fewer individuals had difficulty paying medical costs during the COVID-19 pandemic. According to National Health Interview Surveys, 10.5 million fewer people were in families having problems...
Recent Comments